Immune checkpoint inhibitors-induced autoimmunity: The impact of gender

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Lindsten, 1993, Characterization of CTLA-4 structure and expression on human T cells, J Immunol, 151, 3489, 10.4049/jimmunol.151.7.3489 Okazaki, 2006, The PD-1-PD-L pathway in immunological tolerance, Trends Immunol, 27, 195, 10.1016/j.it.2006.02.001 Bachy, 2014, Anti-PD1 antibody: a new approach to treatment of lymphomas, Lancet Oncol, 15, 7, 10.1016/S1470-2045(13)70587-4 Camacho, 2015, CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations, Cancer Med, 4, 661, 10.1002/cam4.371 Conforti, 2018, Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis, Lancet Oncol, 19, 737, 10.1016/S1470-2045(18)30261-4 Baxi, 2018, Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis, BMJ, 14, k793, 10.1136/bmj.k793 Richter, 2018, Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the mayo clinic experience, Arthritis Rheumatol, 70, 356, 10.1002/art.40397 Buchbinder, 2016, CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition, Am J Clin Oncol, 39, 98, 10.1097/COC.0000000000000239 Egen, 2002, CTLA-4: new insights into its biological function and use in tumor immunotherapy, Nat Immunol, 3, 611, 10.1038/ni0702-611 Fallarino, 1998, B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28, J Exp Med, 188, 205, 10.1084/jem.188.1.205 Linsley, 1996, Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement, Immunity, 4, 535, 10.1016/S1074-7613(00)80480-X Tivol, 1995, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, 541, 10.1016/1074-7613(95)90125-6 Bachmann, 1999, Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous, J Immunol, 163, 1128, 10.4049/jimmunol.163.3.1128 Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027 Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol, 2, 261, 10.1038/85330 Ishida, 2002, Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues, Immunol Lett, 84, 57, 10.1016/S0165-2478(02)00142-6 Okazaki, 2007, PD-1 and PD-1 ligands: from discovery to clinical application, Int Immunol, 19, 813, 10.1093/intimm/dxm057 Qin, 2019, The diverse function of PD-1/PD-L pathway beyond cancer, Front Immunol, 10, 2298, 10.3389/fimmu.2019.02298 Butte, 2007, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, 27, 111, 10.1016/j.immuni.2007.05.016 Zamani, 2016, PD-1/PD-L and autoimmunity: a growing relationship, Cell Immunol, 310, 27, 10.1016/j.cellimm.2016.09.009 Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol Cell Biol, 25, 9543, 10.1128/MCB.25.21.9543-9553.2005 Ortona, 2019, Editorial: sex hormones and gender differences in immune responses, Front Immunol, 10, 1076, 10.3389/fimmu.2019.01076 Zandman-Goddard, 2007, Gender and autoimmunity, Autoimmun Rev, 6, 366, 10.1016/j.autrev.2006.10.001 Dinesh, 2010, PD-1, gender, and autoimmunity, Autoimmun Rev, 9, 583, 10.1016/j.autrev.2010.04.003 Polanczyk, 2006, Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway, J Neurosci Res, 84, 370, 10.1002/jnr.20881 Polanczyk, 2007, Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1), Int Immunol, 19, 337, 10.1093/intimm/dxl151 Shen, 2016, Menopausal status influences the expression of programmed death (PD)-1 and its ligand PD-L1 on immune cells from the human female reproductive tract, Am J Reprod Immunol, 76, 118, 10.1111/aji.12532 Luna, 2010, Female-biased incidence of experimental autoimmune encephalomyelitis reflects sexually dimorphic expression of surface CTLA-4 (CD152) on T lymphocytes, Gend Med, 7, 296, 10.1016/j.genm.2010.08.005 Armand, 2016, Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial, J Clin Oncol, 31, 4199, 10.1200/JCO.2012.48.3685 Malas, 2014, Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review), Oncol Rep, 32, 875, 10.3892/or.2014.3275 Sharon, 2014, Immune checkpoint inhibitors in clinical trials, Chin J Cancer, 33, 434, 10.5732/cjc.014.10122 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Hoos, 2010, Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy, Semin Oncol, 37, 533, 10.1053/j.seminoncol.2010.09.015 Sharma, 2015, Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential, Cell, 161, 205, 10.1016/j.cell.2015.03.030 Botticelli, 2017, The sexist behaviour of immune checkpoint inhibitors in cancer therapy?, Oncotarget, 8, 99336, 10.18632/oncotarget.22242 Pinto, 2018, Gender and outcomes in: an old prognostic variable comes back for targeted therapy and immunotherapy, ESMO Open, 3, 10.1136/esmoopen-2018-000344 Wallis, 2019, Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis, JAMA Oncol, 5, 529, 10.1001/jamaoncol.2018.5904 Conforti, 2019, Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis, J Natl Cancer Inst, 111, 772, 10.1093/jnci/djz094 Wang, 2019, Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer, Cancer Med, 8, 4023, 10.1002/cam4.2280 Grassadonia, 2018, Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical trials, J Clin Med, 7, 10.3390/jcm7120542 Wu, 2018, Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors), Int J Cancer, 143, 45, 10.1002/ijc.31301 Hassler, 2020, Impact of patients’ gender on efficacy of immunotherapy in patients with metastatic kidney cancer: a systematic review and meta-analysis, Clin Genitourin Cancer, 18, 88, 10.1016/j.clgc.2019.09.004 Danlos, 2018, Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease, Eur J Cancer, 91, 21, 10.1016/j.ejca.2017.12.008 Zhai, 2019, Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system, J Immunother Cancer, 7, 10.1186/s40425-019-0754-2 Byun, 2017, Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies, Nat Rev Endocrinol, 13, 195, 10.1038/nrendo.2016.205 Chang, 2019, Endocrine toxicity of Cancer immunotherapy targeting immune checkpoints, Endocr Rev, 40, 17, 10.1210/er.2018-00006 Kassi, 2019, Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma, Cancer Med, 8, 6585, 10.1002/cam4.2533 Yamauchi, 2017, Clinical features of nivolumab-induced thyroiditis: a case series study, Thyroid, 27, 894, 10.1089/thy.2016.0562 Delivanis, 2017, Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms, J Clin Endocrinol Metab, 102, 2770, 10.1210/jc.2017-00448 Yamauchi, 2019, Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab, PLoS One, 14, 10.1371/journal.pone.0216954 Iyer, 2018, Immune-related thyroiditis with immune checkpoint inhibitors, Thyroid, 28, 1243, 10.1089/thy.2018.0116 Ross, 2016, 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis, Thyroid, 26, 1343, 10.1089/thy.2016.0229 Collins, 2017, Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies, Ann Oncol, 28, 2860, 10.1093/annonc/mdx403 Zhang, 2019, Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies, Histopathology de Malet, 2019, Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors, Eur J Cancer, 106, 106, 10.1016/j.ejca.2018.10.006 Chai, 2019, The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non-small cell lung cancer and melanoma: network meta-analysis and systematic review, Front Pharmacol, 10, 1260, 10.3389/fphar.2019.01260 Kalisz, 2019, Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management, Radiographics, 39, 1923, 10.1148/rg.2019190036 Lidar, 2018, Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors, Autoimmun Rev, 17, 284, 10.1016/j.autrev.2018.01.003 Pérez-De-Lis, 2017, Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry), Expert Opin Drug Saf, 16, 1255, 10.1080/14740338.2017.1372421 Michot, 2019, Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?, Eur J Cancer, 122, 72, 10.1016/j.ejca.2019.07.014 Delanoy, 2019, Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study, Lancet Haematol, 6, e48, 10.1016/S2352-3026(18)30175-3 Narváez, 2018, Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy, Autoimmun Rev, 17, 1040, 10.1016/j.autrev.2018.05.002 Richter, 2019, Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients, Arthritis Rheumatol, 71, 468, 10.1002/art.40745 Cappelli, 2017, Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature, Arthritis Care Res (Hoboken), 69, 1751, 10.1002/acr.23177 Chan, 2015, Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma, J Immunother, 38, 37, 10.1097/CJI.0000000000000060 Belkhir, 2017, Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment, Ann Rheum Dis, 76, 1747, 10.1136/annrheumdis-2017-211216 Sapalidis, 2018, Psoriatic arthritis due to nivolumab administration a case report and review of the literature, Respir Med Case Rep, 23, 182 Law-Ping-Man, 2016, Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer, Rheumatology (Oxford), 55, 2087, 10.1093/rheumatology/kew281 Giaccone, 2018, Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study, Lancet Oncol, 19, 347, 10.1016/S1470-2045(18)30062-7 Motzer, 2015, Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial, J Clin Oncol, 33, 1430, 10.1200/JCO.2014.59.0703 Ramos-Casals, 2019, Sicca/Sjögren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR), Clin Exp Rheumatol, 37, 114 Wouters, 2019, Bullous Lupus under nivolumab treatment for lung cancer: a case report with systematic literature review, Anticancer Res, 39, 3003, 10.21873/anticanres.13432 Fadel, 2009, Anti-CTLA4 antibody-induced lupus nephritis, N Engl J Med, 361, 211, 10.1056/NEJMc0904283 Sise, 2019, Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review, Oncologist, 24, 735, 10.1634/theoncologist.2018-0764 Chimenti, 2015, Vasculitides and the complement system: a comprehensive review, Clin Rev Allergy Immunol, 49, 333, 10.1007/s12016-014-8453-8 Crout, 2019, Systemic vasculitis associated with immune check point inhibition: analysis and review, Curr Rheumatol Rep, 21, 10.1007/s11926-019-0828-7 Daxini, 2018, Vasculitis associated with immune checkpoint inhibitors-a systematic review, Clin Rheumatol, 37, 2579, 10.1007/s10067-018-4177-0 Zimmer, 2016, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur J Cancer, 60, 210, 10.1016/j.ejca.2016.02.024 Möhn, 2019, Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma, Melanoma Res, 29, 435, 10.1097/CMR.0000000000000598 Johansen, 2019, Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review, Neurology, 92, 663, 10.1212/WNL.0000000000007235 Kolb, 2018, Neuromuscular complications of immune checkpoint inhibitor therapy, Muscle Nerve, 58, 10, 10.1002/mus.26070 Yuen, 2019, Severe relapse of vaccine-induced guillain-barré syndrome after treatment with nivolumab, J Clin Neuromuscul Dis, 20, 194, 10.1097/CND.0000000000000230 Garon-Czmil, 2019, Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database, Fundam Clin Pharmacol, 33, 241, 10.1111/fcp.12423 Morganstein, 2017, Thyroid abnormalities following the use of CTLA-4 and PD-1 Inhibitors in the treatment of melanoma, Clin Endocrinol (Oxf), 86, 614, 10.1111/cen.13297 Snyders, 2019, Ipilimumab-induced hypophysitis, a single academic center experience, Pituitary, 22, 488, 10.1007/s11102-019-00978-4 Beck, 2006, Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4, J Clin Oncol, 24, 2283, 10.1200/JCO.2005.04.5716 Jain, 2017, Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis, World J Gastroenterol, 23, 2023, 10.3748/wjg.v23.i11.2023 Kao, 2017, Neurological complications associated with anti-programmed death 1 (PD-1) antibodies, JAMA Neurol, 74, 1216, 10.1001/jamaneurol.2017.1912 Bar, 2019, Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study, Eur J Cancer, 120, 122, 10.1016/j.ejca.2019.06.021 Kartolo, 2018, Predictors of immunotherapy-induced immune-related adverse events, Curr Oncol, 25, e403, 10.3747/co.25.4047 Takahashi, 2010, HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves’ disease, J Hum Genet, 55, 323, 10.1038/jhg.2010.20 Ueda, 2003, Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease, Nature, 423, 506, 10.1038/nature01621 Wang, 2018, Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis, JAMA Oncol, 4, 1721, 10.1001/jamaoncol.2018.3923 Ceccarelli, 2020, Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation’ by Braaten et al: another point of view, Ann Rheum Dis, 10.1136/annrheumdis-2019-216867 Percik, 2020, Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors, Autoimmun Rev, 19, 102454, 10.1016/j.autrev.2019.102454 McGonagle, 2020, Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival, Autoimmun Rev, 19, 102456, 10.1016/j.autrev.2019.102456 Hargadon, 2018, Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors, Int Immunopharmacol, 62, 29, 10.1016/j.intimp.2018.06.001